| Patient | Friedrich Nietzsche |
|---|---|
| Date of birth | 1844-10-15 |
| Identifiers | MRN HR-NI019-SYN-TD; SSN (made up) 000-19-5523 |
| Document date | 1881-08-18 |
| Author | Konrad Ellison-Mbatha, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week review after starting galcanezumab and the butalbital taper. [S]
Mr. Nietzsche returns four weeks after the consultation. He finished the taper eight days ago. In the first ten days of the taper his headaches were worse, with six days in a row of headache and vomiting on two, as he had been warned; since then they have eased. His diary shows 14 headache days in the past four weeks, 8 with migraine features, and only 2 headache days in the eight days since the last tablet. Apart from the scheduled taper doses he used acute medicine on 6 days: naproxen on 6, with metoclopramide on 3. He had no tremor, sweating, confusion or seizure; his sleep was worse for a few nights in the second week. The nurse phone check planned for the end of the first taper week did not take place. The first galcanezumab injection left a small red patch for a day. His constipation is no worse. The floaters in his right eye from two weeks ago are fading, with no new flashes. He has had contact lenses fitted and reads more comfortably with the left eye. He has had two CBT-I sessions and sleeps about five hours. [S]
| Element | Detail |
|---|---|
| Taper | Completed eight days ago; rebound headache in the first ten days; no withdrawal symptoms |
| Headache days | 14 in the past four weeks, 8 with migraine features; 2 in the last eight days |
| Acute medicine | Naproxen on 6 days, metoclopramide on 3, besides the taper doses |
| Galcanezumab | Mild redness at the first injection site; constipation unchanged |
| Eyes | Contact lenses fitted; floaters fading |
| Sleep | About five hours; two CBT-I sessions |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Fading floaters in the right eye; no new flashes or shadow |
| Gastrointestinal | Positive | Vomiting on two days early in the taper; constipation no worse |
| Neurological | Positive | Headaches as in the diary; no tremor, confusion or seizure |
| Psychiatric | Negative | Mood steady; no hopelessness or thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, one or two tablets as needed for headache, taken on about 16 days a month, up to four tablets a day (prescribed abroad) | One or two tablets as needed, about 16 days a month, up to four a day | Oral route | 1880-11-03 to 1881-07-21 | stopped | S |
| Ibuprofen 200 mg oral tablet, two tablets as needed for headache on days without the combination tablets, about 4 days a month (over the counter) | Two tablets as needed, about 4 days a month | Oral route | 1880-11-03 to 1881-07-21 | stopped | S |
| Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, scheduled taper: one tablet twice a day for 7 days, then one tablet a day for 7 days, then one tablet every other day for 7 days, then stop | Scheduled taper over three weeks: twice a day, then once a day, then every other day, then stop; not for extra doses | Oral route | 1881-07-21 to 1881-08-10 | completed | S |
| Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a week | One tablet at attack onset, may repeat once after 12 hours; no more than two days a week | Oral route | 1881-07-21 | active | S |
| Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a week | One tablet with the acute medicine when nausea is present, no more than once a day | Oral route | 1881-07-21 | active | S |
| Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine prevention | Loading dose of 240 mg (two injections) on the first day, then 120 mg every four weeks | Subcutaneous route | 1881-07-21 | active | S |
| Sumatriptan 100 mg oral tablet, one tablet early in a migraine attack, may repeat once after 2 hours; no more than two days a week and no more than eight days a month | One tablet at attack onset, may repeat once after 2 hours; up to 200 mg a day, no more than eight days a month | Oral route | 1881-08-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1881-08-18 | Body height | 174 | cm | S |
| 1881-08-18 | Body weight | 66.6 | kg | S |
| 1881-08-18 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 1881-08-18 | Systolic blood pressure | 114 | mm[Hg] | S |
| 1881-08-18 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1881-08-18 | Heart rate | 64 | /min | S |
| 1881-08-18 | Respiratory rate | 14 | /min | S |
| 1881-08-18 | Body temperature | 36.6 | Cel | S |
| 1881-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 1881-08-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 114/72, pulse 64 |
| Skin | First injection site on the abdomen healed |
| Neurological | No tremor; normal examination |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Frequent disabling headaches on about 20 days a month, with nausea, vomiting and light sensitivity, mostly right-sided, since childhood and more frequent over the past year, with a combination headache tablet containing butalbital taken on about 16 days a month; under evaluation with a headache diary, MRI, syphilis serology and a headache medicine consultation | resolved | confirmed | R51.9 | S — Synthetic presenting problem anchored to his documented headaches; superseded when the consultation confirmed chronic migraine with medication overuse headache. |
| Chronic migraine without aura (15 or more headache days a month for more than three months, at least 8 with migraine features); ICHD-3 criteria met in a two-week diary; MRI of the brain normal; synthetic modern diagnosis linked to his documented headaches, which historians interpret differently | active | confirmed | G43.709 | S — Synthetic modern diagnosis made at the consultation; the historical diagnosis is disputed (CLM-0014), so this is not a claim about his real diagnosis. |
| Medication overuse headache from a butalbital, acetaminophen and caffeine combination on 10 or more days a month for more than three months, with ibuprofen on other days; resolved after a three-week taper and withdrawal | active | confirmed | G44.40 | S — Synthetic diagnosis made at the consultation, anchored to his documented use of many medicines and sedatives; not a claim about his real medicines. |
| High myopia in both eyes, much worse in the right eye, since early childhood, with long-standing poor vision in the right eye and unequal pupils; comprehensive eye examination booked | active | confirmed | H52.13 | S — Synthetic modern coding of his documented severe myopia. |
| Pathologic (degenerative) myopia of the right eye with patchy chorioretinal atrophy of the macula, a posterior staphyloma and a tilted optic disc; no choroidal neovascularization on OCT; best corrected vision 20/100 in the right eye | active | confirmed | H44.2E1 | S — Synthetic finding of the comprehensive eye examination, anchored to his documented poor right eye and the retrospective reading of it as myopic degeneration; not a claim about his real eyes. |
| Chronic insomnia, with difficulty falling asleep and early waking, worse on headache nights; no sleep medicine at intake | active | confirmed | G47.00 | S — Synthetic sleep problem anchored to his documented severe insomnia; not a claim about his real sleep. |
| Acute posterior vitreous detachment of the right eye, with flashes and a floater, without a retinal break, detachment or vitreous hemorrhage on dilated examination, in an eye with pathologic myopia | active | confirmed | H43.811 | S — Synthetic acute eye problem in a highly myopic eye; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Red-flag screen (SNNOOP10): systemic signs, neurological signs, sudden onset, onset after 50, change in pattern, positional or Valsalva features, papilledema, progressive course | Every visit | Completed today | No red flags |
| Survey | Headache diary: headache days, migraine days, attack features, triggers | Every visit | Completed today | 14 headache days in four weeks, 8 with migraine features, including the withdrawal weeks; 2 in the last eight days |
| Medication safety | Acute-medicine days (overuse limits: combination analgesics, triptans fewer than 10 days a month, simple analgesics fewer than 15) | Every visit | Completed today | Naproxen on 6 days besides the scheduled taper doses; no butalbital since the taper ended |
| Medication safety | Barbiturate withdrawal: tremor, sweating, agitation, insomnia, confusion, seizures; rebound headache | During the three-week taper and at the first visit after it | Deferred | The nurse phone check planned for the end of the first taper week did not take place. No harm resulted: he had rebound headache only, with no tremor, sweating, confusion or seizure, and he finished the taper as written. Corrective action: phone checks during any future taper are booked at the visit that starts it |
| Medication safety | Galcanezumab tolerability: injection sites, constipation, blood pressure, hypersensitivity | Before starting and at each injection visit | Completed today | Mild redness at the first site for a day; constipation unchanged; blood pressure 114/72; second dose given today |
| Medication safety | Cardiovascular screen before a triptan | Before the first triptan prescription | Completed today | No chest pain, vascular disease, uncontrolled blood pressure or smoking; blood pressure 114/72 |
| Examination | Preventive efficacy (at least 50% fewer monthly migraine days; headache days below 15 a month) | At three months on treatment | Due | Four weeks on galcanezumab, including the withdrawal weeks; judged at about three months |
| Survey | Disability (MIDAS, recorded as its five items, and HIT-6) | At baseline and after two to three months of treatment | Due | Repeat at the eight-week review |
| Survey | Mood (PHQ-9) and anxiety (GAD-7), with direct questions about hopelessness and self-harm | At baseline and at two to three months; questions at every visit | Due | PHQ-9 and GAD-7 at the eight-week review; no hopelessness or thoughts of self-harm today |
| Examination | Dilated re-examination after an acute posterior vitreous detachment | Within six weeks of the detachment, sooner with new symptoms | Due | Detachment two weeks ago without a break; floaters fading; re-examination at the eight-week review |
| Examination | Contact lens fit and corrected vision | After fitting | Completed today | Lenses fitted; left eye 20/20 and right eye 20/100 with lenses |
| Self-management | Sleep: hours, sleep diary, insomnia severity; no sedative sleeping tablets | Every visit | Completed today | About five hours; two CBT-I sessions; no sleeping tablets |
Goal progress:
Guideline basis: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024); European Academy of Neurology guideline on the management of medication-overuse headache (2020); European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013); Refractive Errors Preferred Practice Pattern (2023); Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (2025); Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Preventive visit in two weeks. Eight-week review in four weeks with the third galcanezumab injection and the repeat dilated eye examination. Same-day eye care for new flashes, a shower of floaters or a shadow. Next scheduled visit 1881-09-01: periodic adult preventive visit. [S]